Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France on volume and cost of drug deliveries, assessed with administrative databases

• Published in: Seminars in arthritis and rheumatism Vol. 50; no. 6; pp. 1307 - 1313
• Main Authors: Mari, K., Rannou, F., Guillemin, F., Elegbede, M., Gueyffier, F., Badot, G., Mistretta, F.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-12-2020; WB Saunders
• Subjects: Cost; Hospitalization; Life Sciences; NSAID; Osteoarthritis; Reimbursement; SYSADOA; Reimbursement; Hospitalization; Osteoarthritis; Cost; NSAID; SYSADOA; AINS; Remboursement; Coût; Arthrose; Hospitalisation
• ISSN: 0049-0172; 1532-866X
• DOI: 10.1016/j.semarthrit.2020.09.001

As one of the leading causes of disability in adults worldwide, its toll on patients and its economic burden for payers are substantial. The issue of change in OA management with the evolution of reimbursement schemes needs to be addressed.
To assess the impact of terminating the reimbursement of symptomatic slow-acting drugs in OA (SYSADOAs) in France in terms of volume and cost, from a healthcare payer perspective.
We obtained costs and volumes from French public national databases. We considered three exposure periods around cutoff dates according to decisions of decreased then terminated SYSADOA reimbursement. The periods included 19 345 (control), 20 066 (secondary), and 16 200 (primary) patients, respectively. Mean ages were 66.2 (±11.8), 65.3 (±11.6) and 64.6 (±11.5) years and about 70% were women. The volume of nonsteroidal anti-inflammatory drug (NSAID) deliveries estimated by defined daily doses (DDDs) decreased during the periods from 40.5 (±76.3) DDDs per patient in 2008 to 29.6 (±66.4) in 2015. The volume of analgesic deliveries increased slowly over the three periods, from 70.2 (±108.9) DDDs in 2008 to 76.9 (±123.1) in 2015 for all patients.
Our results did not show a measurable impact of terminating SYSADOA reimbursement on the delivery of NSAIDs and analgesics or on hospitalizations. However, neither do they allow for concluding that terminating SYSADOA reimbursement did not generate an increase in deliveries of non-reimbursed drugs, with their associated potential risks for public health.